| Author |
Cheng, H-W Liang, Y-H Kuo, Y-L Chuu, C-P Lin, C-Y Lee, M-H Wu, A. T. H. Yeh, C-T Chen, E. I-T Whang-Peng, J. Su, C-L Huang, C-Y F. |
| Description |
Country affiliation: Taiwan Author Affiliation: Cheng HW ( Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan.); Liang YH ( Department of Biotechnology and Laboratory Science in Medicine, National Yang-Ming University, Taipei, Taiwan.); Kuo YL ( Department of Computer Science and Information Engineering, National Taiwan University, Taipei, Taiwan.); Chuu CP ( Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli, Taiwan.); Lin CY ( 1] Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli, Taiwan [2] Institute of Cancer Research, National Health Research Institutes, Miaoli, Taiwan.); Lee MH ( Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan.); Wu AT ( Department of Radiation, School of Medicine, Taipei Medical University, Taipei, Taiwan.); Yeh CT ( Graduate Institute of Clinical Medicine, Taipei Medical University, Taipei, Taiwan.); Chen EI ( Department of Biotechnology and Laboratory Science in Medicine, National Yang-Ming University, Taipei, Taiwan.); Whang-Peng J ( Municipal Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.); Su CL ( Program of Nutritional Science and Education, Department of Human Development and Family Studies, National Taiwan Normal University, Taipei, Taiwan.); Huang CY ( 1] Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan [2] Department of Biotechnology and Laboratory Science in Medicine, National Yang-Ming University, Taipei, Taiwan.) |
| Abstract |
Glioblastoma (GBM) is a common and malignant tumor with a poor prognosis. Glioblastoma stem cells (GSCs) have been reported to be involved in tumorigenesis, tumor maintenance and therapeutic resistance. Thus, to discover novel candidate therapeutic drugs for anti-GBM and anti-GSCs is an urgent need. We hypothesized that if treatment with a drug could reverse, at least in part, the gene expression signature of GBM and GSCs, this drug may have the potential to inhibit pathways essential in the formation of GBM and thereby treat GBM. Here, we collected 356 GBM gene signatures from public databases and queried the Connectivity Map. We systematically evaluated the in vitro antitumor effects of 79 drugs in GBM cell lines. Of the drugs screened, thioridazine was selected for further characterization because it has potent anti-GBM and anti-GSCs properties. When investigating the mechanisms underlying the cytocidal effects of thioridazine, we found that thioridazine induces autophagy in GBM cell lines, and upregulates AMPK activity. Moreover, LC3-II was upregulated in U87MG sphere cells treated with thioridazine. In addition, thioridazine suppressed GBM tumorigenesis and induced autophagy in vivo. We not only repurposed the antipsychotic drug thioridazine as a potent anti-GBM and anti-GSCs agent, but also provided a new strategy to search for drugs with anticancer and anticancer stem cell properties. |
| Subject Keyword |
Research Support, Non-u.s. Gov't Glioblastoma Gene Expression Profiling Mice, Scid Autophagy Brain Neoplasms Antipsychotic Agents Genetics Physiology Cell Survival Drug Therapy Pharmacology Neoplastic Stem Cells Random Allocation Drug Effects Xenograft Model Antitumor Assays Discipline Cell Biology Pathology Thioridazine Animals Cell Line, Tumor Mice, Inbred Nod Drug Screening Assays, Antitumor |
